Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
While new data show Merck & Co’s Keytruda (pembrolizumab) besting Adcetris (brentuximab vedotin) in classical Hodgkin lymphoma (cHL), analysts are doubtful the star checkpoint inhibitor will sweep all before it in this indication. 3 March 2020
Biotechnology
As part of US biopharma major AbbVie’s $6.3 billion acquisition of Ireland-incorporated Allergan announced last year, the European Commission has approved the divestiture of brazikumab, an investigational interleukin (IL)-23 inhibitor in development for autoimmune diseases, to AstraZeneca 3 March 2020
Biotechnology
East Coast, USA-based Karyopharm Therapeutics has announced positive topline results from the Phase III BOSTON study of Xpovio (selinexor). 3 March 2020
Biotechnology
The US Food and Drug Administration has granted Breakthrough Therapy designation to Esbriet (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD) 3 March 2020
Biotechnology
Some eight weeks earlier than expected, the US Food and Drug Administration has approved Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have 3 March 2020
Biotechnology
Privately-held UK-based T cell receptor (TCR) biotech firm Immunocore today announced the completion of its Series B private financing round, generating more than $130 million. 2 March 2020
Biotechnology
The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC) for patients with chronic pain due to moderate-to-severe osteoarthritis (OA), who have experienced inadequate relief with other analgesics. 2 March 2020
Biotechnology
NHS England said on Saturday that it will fund a life-changing treatment for people with rare conditions causing repeated bouts of fever, joint pain and swelling. 2 March 2020
Biotechnology
German pharma and sciences firm Merck KGaA says that its Erbitux (cetuximab) has been granted approval by China’s National Medical Products Administration (NMPA) for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in combination with platinum-based therapy with fluorouracil. 2 March 2020
Biotechnology
Confirming rumors developing over the weekend that pushed the share of USA-based Forty Seven up as much as 35%, to a market capitalization of about $2.3 billion, US biotech major Gilead Sciences this morning announced that it has entered into a definitive agreement to acquire the company for $95.50 per share in cash, representing a premium of 64.7% to the stock's Friday closing price. 2 March 2020
Biotechnology
US biotech firm Clovis Oncology today announced that Rubraca (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of Medicines and Health Products approval of the drug for reimbursement. 2 March 2020
Biotechnology
The VIALE-C (M16-043) trial of Venclexta (venetoclax) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of statistically-significant improvement of overall survival (OS) for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy at the time of the planned analysis. 29 February 2020
Biotechnology
Biohaven Pharmaceutical Holding late Thursday gained regulatory approval for its migraine treatment drug to join the already competitive market sector, with the news sending its shares up 5.3% to $40.82 in after-hours trading, after falling 8.5% in the regular session. 28 February 2020
Biotechnology
After the bell on Thursday US biotech major Biogen and genomic medicines company Sangamo Therapeutics announced that they have executed a global licensing collaboration agreement, that could be worth over $2.5 billion, with the news sending the latter’s shares almost 40% higher to $9.31 in after-hours trading. 28 February 2020
Biotechnology
Data on Vitrakvi (larotrectinib) in adult and pediatric patients with TRK fusion cancer shows the need to identify suitable patients through genomic testing, says German pharma major Bayer. 27 February 2020
Biotechnology
Germany’s Boehringer Ingelheim and privately-held US firm Trutino Biosciences have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform. 27 February 2020
Biotechnology
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation for its experimental CD30-directed autologous Car-T cell candidate. 27 February 2020
Biotechnology
A vote of the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) on Eli Lilly’s Cymramza (ramucirumab) has narrowly come out in favor of using the drug in combination with erlotinib in a lung cancer indication. 27 February 2020
Biotechnology
The Brazilian Health Regulatory Agency (ANVISA) has approved Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. 27 February 2020
Biotechnology
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Nerlynx (neratinib) in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. 27 February 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze